Resources

oncology

Patient-Derived Organoids: A New Frontier in ADC Development

oncology

Patient-derived organoids as translational avatars for KRAS research

immuno-oncology

Transforming T cell therapy for solid tumors using patient-derived HUB Organoids®

infectious disease

Patient-derived Organoids: Transforming Infectious Disease Research and Drug Development

Dr. Sylvia Boj, Chief Scientific Officer

Oncology

Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-omic Data

Dr. Sylvia Boj, Chief Scientific Officer Daniella Patton, Principal Scientific Consultant, Genedata

Oncology

Mini-Organs, Major Breakthroughs: Accelerating Oncology Drug Development

Dr. Sylvia Boj, Chief Scientific Officer

INFECTION DISEASE

Patient-Derived Airway Organoids for Modelling Rhinovirus Infection

inflammatory bowel disease

3D In-Vitro Fibroblast-Patient Derived Organoid Co-Culture: A High-Throughput Platform for Inflammatory Bowel Disease Drug Development

immuno-oncology

Reconstructing tumor microenvironment with patient-derived organoids for derisking Immuno-Oncology therapies

oncology

Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity

oncology

Resistant PDO models: Unraveling drug resistance mechanisms for discovering new drug targets

oncology

Patient-derived organoids: A pre-clinical model to assess infection and killing capacity of viral vectors for cancer therapy

oncology

How we supported our client in advancing biomarker discovery and translational ADC development

Toxicology

How we helped our client anticipate on- and off-target toxicity using patient-derived organoids

Toxicology

How we supported our client translate animal toxicity data to human-relevant insights and identify a therapeutic window

oncology

Accelerating oncology drug discovery with HUB Organoids®

Blog

RASolute 302 Trial: A New Era for RAS-Targeted Drug Discovery

When the first Kaplan-Meier curve from the Phase 3 RASolute 302 trial appeared on the screens at the 2026 ASCO...

Blog

Regulators Embrace Organoids: Inside the FDA’s Shift Away from Animal Model

Last week, the FDA announced a transformative shift in drug development policy that monoclonal antibody (mAb) therapeutics may no longer...

Blog

Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery

In this "Ask the Expert" interview, Dr. Javier Frias Aldeguer, Senior Scientist at HUB Organoids shares insights into the inFOCUS...

Organoid Technology

From Patient to Platform

toxicology

HUB Organoids in Preclinical Toxicology

inflammatory bowel disease

PDO Monolayer for Inflammatory Bowel Disease (IBD)

oncology

Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Clin Cancer Res | 2025 Dec

oncology

Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond

npj Biomed. Innov. | 2026 Feb

oncology

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

J Exp Clin Cancer Res | 2024 Feb

oncology

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Cell Rep | April 2023

toxicology

Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules

Eur J Pharm Sci | July 2023

infectious disease

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

eLife | July 2021